Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-07-06 | Goldstein Joseph L (Director) | Sale | 2,000 | 370.00 | 740,000 |
| 2018-07-06 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 57.11 | 114,220 |
| 2018-07-05 | Goldstein Joseph L (Director) | Sale | 2,000 | 360.00 | 720,000 |
| 2018-07-05 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 57.11 | 114,220 |
| 2018-06-21 | Vagelos P Roy (Chairman of the Board) | Sale | 74,710 | 329.62 | 24,625,984 |
| 2018-06-20 | Vagelos P Roy (Chairman of the Board) | Option Ex | 153,274 | 16.80 | 2,575,003 |
| 2018-06-08 | Sanofi | Sale | 121,601 | 309.31 | 37,611,918 |
| 2018-05-24 | Stahl Neil (EVP Research and Development) | Sale | 11,407 | 295.09 | 3,366,091 |
| 2018-05-23 | Stahl Neil (EVP Research and Development) | Option Ex | 26,736 | 30.63 | 818,923 |
| 2018-05-10 | Sing George L (Director) | Sale | 13,000 | 286.50 | 3,724,500 |
| 2018-05-09 | Sing George L (Director) | Sale | 7,000 | 285.29 | 1,997,030 |
| 2018-03-19 | Goldstein Joseph L (Director) | Sale | 2,000 | 350.02 | 700,040 |
| 2018-03-19 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 57.11 | 114,220 |
| 2018-03-14 | Goldstein Joseph L (Director) | Sale | 2,000 | 340.00 | 680,000 |
| 2018-03-14 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 57.11 | 114,220 |
| 2018-01-16 | Fenimore Christopher R. (VP Controller) | Option Ex | 150 | 21.25 | 3,187 |
| 2018-01-02 | Sing George L (Director) | Option Ex | 15,000 | 23.84 | 357,600 |
| 2017-12-13 | Yancopoulos George (President & CSO) | Option Ex | 195,438 | 21.92 | 4,284,000 |
| 2017-12-13 | Schleifer Leonard S (President & CEO) | Option Ex | 250,000 | 21.92 | 5,480,000 |
| 2017-12-11 | Vagelos P Roy (Chairman of the Board) | Option Ex | 153,969 | 21.92 | 3,375,000 |
| 2017-10-05 | Brown Michael S (Director) | Sale | 1,500 | 475.00 | 712,500 |
| 2017-10-05 | Brown Michael S (Director) | Option Ex | 1,500 | 177.82 | 266,730 |
| 2017-09-29 | Baker Charles A (Director) | Sale | 2,000 | 450.00 | 900,000 |
| 2017-09-29 | Baker Charles A (Director) | Option Ex | 2,000 | 18.61 | 37,220 |
| 2017-09-06 | Landry Robert E (SVP Finance & CFO) | Sale | 474 | 497.57 | 235,846 |
| 2017-09-05 | Landry Robert E (SVP Finance & CFO) | Sale | 189 | 501.11 | 94,708 |
| 2017-09-01 | Landry Robert E (SVP Finance & CFO) | Option Ex | 3,000 | 272.70 | 818,100 |
| 2017-08-31 | Landry Robert E (SVP Finance & CFO) | Sale | 427 | 493.14 | 210,569 |
| 2017-08-30 | Landry Robert E (SVP Finance & CFO) | Option Ex | 2,000 | 272.70 | 545,400 |
| 2017-08-25 | Sanofi | Buy | 72,378 | 482.99 | 34,957,488 |
| 2017-08-24 | Sanofi | Buy | 105,820 | 481.79 | 50,983,335 |
| 2017-08-23 | Landry Robert E (SVP Finance & CFO) | Sale | 468 | 476.35 | 222,929 |
| 2017-08-23 | Sanofi | Buy | 60,595 | 478.30 | 28,982,467 |
| 2017-08-22 | Landry Robert E (SVP Finance & CFO) | Option Ex | 2,000 | 272.70 | 545,400 |
| 2017-08-22 | Vagelos P Roy (Chairman of the Board) | Sale | 31,944 | 477.04 | 15,238,533 |
| 2017-08-21 | Vagelos P Roy (Chairman of the Board) | Sale | 24,269 | 471.16 | 11,434,582 |
| 2017-08-18 | Vagelos P Roy (Chairman of the Board) | Sale | 2,900 | 470.15 | 1,363,435 |
| 2017-08-17 | Vagelos P Roy (Chairman of the Board) | Sale | 1,305 | 470.00 | 613,350 |
| 2017-08-16 | Vagelos P Roy (Chairman of the Board) | Sale | 10,986 | 470.17 | 5,165,287 |
| 2017-08-16 | Vagelos P Roy (Chairman of the Board) | Option Ex | 153,969 | 21.92 | 3,375,000 |
| 2017-08-10 | Terifay Robert J (EVP Commercial) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2017-08-08 | Landry Robert E (SVP Finance & CFO) | Sale | 526 | 471.75 | 248,143 |
| 2017-08-07 | Landry Robert E (SVP Finance & CFO) | Option Ex | 2,000 | 272.70 | 545,400 |
| 2017-06-22 | Aberman Michael S (SVP Strategy Investor Relation) | Sale | 2,269 | 533.05 | 1,209,488 |
| 2017-06-22 | Stahl Neil (EVP Research and Development) | Sale | 8,306 | 531.82 | 4,417,321 |
| 2017-06-21 | Aberman Michael S (SVP Strategy Investor Relation) | Option Ex | 4,500 | 30.63 | 137,835 |
| 2017-06-21 | Stahl Neil (EVP Research and Development) | Option Ex | 20,000 | 30.63 | 612,600 |
| 2017-06-20 | Goldstein Joseph L (Director) | Sale | 1,000 | 500.01 | 500,010 |
| 2017-06-20 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 273.67 | 273,670 |
| 2017-06-20 | Brown Michael S (Director) | Sale | 3,000 | 500.00 | 1,500,000 |
| 2017-06-20 | Brown Michael S (Director) | Option Ex | 3,000 | 177.82 | 533,460 |
| 2017-06-16 | Terifay Robert J (EVP Commercial) | Sale | 21,147 | 468.19 | 9,900,813 |
| 2017-06-15 | Terifay Robert J (EVP Commercial) | Option Ex | 48,750 | 52.03 | 2,536,462 |
| 2017-06-15 | Stahl Neil (EVP Research and Development) | Sale | 8,567 | 468.20 | 4,011,112 |
| 2017-06-14 | Stahl Neil (EVP Research and Development) | Option Ex | 20,295 | 21.25 | 431,268 |
| 2017-06-12 | Brown Michael S (Director) | Sale | 2,000 | 473.60 | 947,190 |
| 2017-06-12 | Brown Michael S (Director) | Option Ex | 2,000 | 177.82 | 355,640 |
| 2017-06-09 | Goldstein Joseph L (Director) | Sale | 1,000 | 482.55 | 482,550 |
| 2017-06-09 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 273.67 | 273,670 |
| 2017-06-02 | Stahl Neil (EVP Research and Development) | Sale | 2,812 | 476.06 | 1,338,689 |
| 2017-06-02 | Sanofi | Buy | 136,050 | 475.63 | 64,709,869 |
| 2017-06-01 | Stahl Neil (EVP Research and Development) | Option Ex | 10,544 | 207.05 | 2,183,135 |
| 2017-05-25 | Vagelos P Roy (Chairman of the Board) | Sale | 9,295 | 458.39 | 4,260,735 |
| 2017-03-29 | Brown Michael S (Director) | Sale | 1,000 | 400.00 | 400,000 |
| 2017-03-29 | Brown Michael S (Director) | Option Ex | 1,000 | 177.82 | 177,820 |
| 2017-01-11 | Sanofi | Buy | 87,298 | 371.01 | 32,388,605 |
| 2017-01-03 | Sing George L (Director) | Option Ex | 14,000 | 19.69 | 275,660 |
| 2016-12-15 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 195,079 | 20.32 | 3,964,005 |
| 2016-12-15 | Schleifer Leonard S (President & CEO) | Option Ex | 250,000 | 20.32 | 5,080,000 |
| 2016-12-12 | Baker Charles A (Director) | Sale | 3,000 | 392.48 | 1,177,446 |
| 2016-12-12 | Baker Charles A (Director) | Option Ex | 3,000 | 18.61 | 55,830 |
| 2016-11-15 | Ryan Arthur F (Director) | Sale | 2,000 | 429.34 | 858,680 |
| 2016-11-14 | Goldstein Joseph L (Director) | Sale | 2,125 | 450.00 | 956,250 |
| 2016-11-14 | Goldstein Joseph L (Director) | Option Ex | 2,125 | 273.67 | 581,548 |
| 2016-11-07 | Vagelos P Roy (Chairman of the Board) | Option Ex | 76,895 | 20.32 | 1,562,506 |
| 2016-07-29 | Goldstein Joseph L (Director) | Sale | 2,125 | 425.00 | 903,125 |
| 2016-07-29 | Goldstein Joseph L (Director) | Option Ex | 2,125 | 273.67 | 581,548 |
| 2016-06-14 | Sanofi | Buy | 64,731 | 364.22 | 23,576,583 |
| 2016-05-24 | Ryan Arthur F (Director) | Sale | 1,000 | 396.64 | 396,640 |
| 2016-05-18 | Van Plew Daniel P (EVP & General Mgr Industrial O) | Sale | 4,413 | 385.77 | 1,702,403 |
| 2016-05-17 | Van Plew Daniel P (EVP & General Mgr Industrial O) | Option Ex | 9,460 | 30.63 | 289,759 |
| 2016-05-12 | Vagelos P Roy (Chairman of the Board) | Option Ex | 230,684 | 20.32 | 4,687,498 |
| 2016-04-06 | Goldstein Joseph L (Director) | Sale | 2,000 | 425.00 | 850,000 |
| 2016-04-06 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 177.82 | 177,820 |
| 2016-04-01 | Goldstein Joseph L (Director) | Sale | 2,000 | 400.00 | 800,000 |
| 2016-04-01 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 177.82 | 355,640 |
| 2016-03-21 | Goldstein Joseph L (Director) | Sale | 2,000 | 375.00 | 750,000 |
| 2016-03-21 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 177.82 | 355,640 |
| 2016-01-12 | Sanofi | Buy | 83,938 | 463.51 | 38,905,850 |
| 2015-12-29 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 3,954 | 552.08 | 2,182,924 |
| 2015-12-29 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 3,954 | 52.03 | 205,726 |
| 2015-12-17 | Aberman Michael S (SVP Strategy Investor Relation) | Option Ex | 4,000 | 24.00 | 96,000 |
| 2015-12-16 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2015-12-16 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2015-12-16 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2015-12-16 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2015-12-16 | Stahl Neil (EVP Research and Development) | Option Ex | 1,921 | 52.03 | 99,949 |
| 2015-12-10 | Brown Michael S (Director) | Sale | 3,000 | 545.37 | 1,636,110 |
| 2015-12-10 | Brown Michael S (Director) | Option Ex | 3,000 | 177.82 | 533,460 |
| 2015-12-02 | Yancopoulos George (President Regeneron Laboratori) | Sale | 43,348 | 548.99 | 23,797,401 |
| 2015-11-18 | Sing George L (Director) | Sale | 3,500 | 580.00 | 2,030,000 |
| 2015-11-18 | Sing George L (Director) | Option Ex | 3,000 | 19.69 | 59,070 |
| 2015-11-18 | Vagelos P Roy (Chairman of the Board) | Sale | 17,240 | 587.57 | 10,129,706 |
| 2015-11-09 | Stahl Neil (EVP Research and Development) | Sale | 22,101 | 560.84 | 12,395,058 |
| 2015-11-06 | Stahl Neil (EVP Research and Development) | Sale | 20,000 | 563.33 | 11,266,600 |
| 2015-11-05 | Stahl Neil (EVP Research and Development) | Option Ex | 100,000 | 25.94 | 2,594,000 |
| 2015-11-03 | Vagelos P Roy (Chairman of the Board) | Sale | 3,985 | 580.23 | 2,312,216 |
| 2015-11-02 | Yancopoulos George (President Regeneron Laboratori) | Sale | 43,348 | 571.07 | 24,754,612 |
| 2015-11-02 | Vagelos P Roy (Chairman of the Board) | Sale | 13,257 | 580.18 | 7,691,446 |
| 2015-10-30 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 182,818 | 11.64 | 2,128,001 |
| 2015-10-06 | Sanofi | Buy | 91,578 | 466.38 | 42,209,165 |
| 2015-09-23 | Sanofi | Buy | 147,209 | 532.00 | 78,315,924 |
| 2015-09-21 | Brown Michael S (Director) | Sale | 3,000 | 551.55 | 1,654,649 |
| 2015-09-21 | Brown Michael S (Director) | Option Ex | 3,000 | 57.11 | 171,330 |
| 2015-09-17 | Baker Charles A (Director) | Sale | 5,000 | 550.00 | 2,750,000 |
| 2015-09-17 | Baker Charles A (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2015-09-02 | Schleifer Leonard S (President & CEO) | Option Ex | 7,226 | 402.69 | 2,909,837 |
| 2015-09-01 | Larosa Joseph J (SVP General Counsel and Secret) | Option Ex | 1,689 | 59.20 | 99,988 |
| 2015-08-14 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 23,485 | 574.13 | 13,483,419 |
| 2015-08-13 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 60,361 | 116.85 | 7,053,182 |
| 2015-08-12 | Poon Christine A (Director) | Sale | 112 | 564.16 | 63,186 |
| 2015-08-11 | Poon Christine A (Director) | Option Ex | 470 | 273.67 | 128,624 |
| 2015-08-06 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 4,028 | 584.32 | 2,353,632 |
| 2015-08-06 | Terifay Robert J (SVP Commercial) | Sale | 13,423 | 589.91 | 7,918,335 |
| 2015-08-06 | Gilman Alfred G (Director) | Sale | 5,000 | 587.90 | 2,939,515 |
| 2015-08-06 | Gilman Alfred G (Director) | Option Ex | 5,000 | 57.11 | 285,550 |
| 2015-08-05 | Landry Robert E (SVP Finance & CFO) | Sale | 4,000 | 592.51 | 2,370,028 |
| 2015-08-05 | Landry Robert E (SVP Finance & CFO) | Option Ex | 4,000 | 272.70 | 1,090,800 |
| 2015-08-05 | Tessier-lavigne Marc (Director) | Sale | 5,000 | 590.83 | 2,954,150 |
| 2015-08-05 | Tessier-lavigne Marc (Director) | Option Ex | 5,000 | 57.11 | 285,550 |
| 2015-08-05 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 8,700 | 25.94 | 225,678 |
| 2015-08-05 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 5,000 | 585.75 | 2,928,775 |
| 2015-08-05 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 5,000 | 270.43 | 1,352,150 |
| 2015-08-05 | Terifay Robert J (SVP Commercial) | Option Ex | 32,500 | 30.63 | 995,475 |
| 2015-08-04 | Goldstein Joseph L (Director) | Sale | 2,000 | 586.00 | 1,172,000 |
| 2015-07-27 | Sanofi | Buy | 10,639 | 536.74 | 5,710,366 |
| 2015-07-15 | Goldstein Joseph L (Director) | Sale | 2,000 | 550.00 | 1,100,000 |
| 2015-06-22 | Goldstein Joseph L (Director) | Sale | 2,000 | 526.85 | 1,053,700 |
| 2015-05-27 | Sing George L (Director) | Sale | 5,000 | 515.00 | 2,575,000 |
| 2015-05-27 | Sing George L (Director) | Option Ex | 5,000 | 19.69 | 98,450 |
| 2015-05-27 | Ingram Robert Alexander (Director) | Sale | 1,379 | 513.39 | 707,964 |
| 2015-05-26 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 18,370 | 508.81 | 9,346,784 |
| 2015-05-22 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 40,050 | 25.94 | 1,038,897 |
| 2015-05-22 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 13,000 | 515.60 | 6,702,800 |
| 2015-05-22 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 13,464 | 104.88 | 1,412,104 |
| 2015-05-22 | Goldstein Joseph L (Director) | Sale | 4,000 | 514.27 | 2,057,100 |
| 2015-05-22 | Ingram Robert Alexander (Director) | Option Ex | 6,667 | 293.53 | 1,956,964 |
| 2015-05-15 | Brown Michael S (Director) | Sale | 5,000 | 495.00 | 2,475,000 |
| 2015-05-15 | Brown Michael S (Director) | Option Ex | 5,000 | 57.11 | 285,550 |
| 2015-04-08 | Landry Robert E (SVP Finance & CFO) | Option Ex | 10,000 | 272.70 | 2,727,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.